Irinotecan Accordpharma

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Accordpharma, is a topoisomerase I inhibitor presented as an intravenous solution for infusion use. It is indicated for the treatment of colorectal cancer and metastatic colorectal cancer in adult patients. GNH USA supplies Irinotecan Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Accordpharma acts on malignant cells of the colorectal cancer pathway. - Colorectal cancer: provides cytotoxic therapy to shrink or control primary tumors. - Metastatic colorectal cancer: used to reduce tumor burden and improve survival in advanced disease. - Adjuvant therapy for colorectal cancer: administered after surgery to lower the risk of recurrence.

Irinotecan may cause a range of adverse reactions during treatment.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may need anti‑emetic support. - Fatigue: generalized tiredness affecting daily activities. - Alopecia: temporary hair loss. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe colitis or intestinal perforation from uncontrolled diarrhea. - Hepatic toxicity: elevated liver enzymes or jaundice. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe mucositis: painful inflammation of the mouth and gastrointestinal lining.

Prior to initiating Irinotecan therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity. - Renal function: assess creatinine clearance and adjust if necessary. - Hepatic function: monitor liver enzymes; dose may need modification in impairment. - Myelosuppression: perform regular complete blood counts to detect neutropenia. - Diarrhea: implement prophylactic loperamide and educate patients on early reporting. - Pregnancy: avoid use unless the potential benefit justifies the risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): can increase active metabolite levels and toxicity.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect metabolism and require dose adjustment. - Warfarin: potential for increased bleeding risk; monitor INR. - Other myelosuppressive agents: additive bone‑marrow suppression warrants close blood count monitoring.